Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

SELL
$21.39 - $49.64 $176,724 - $410,125
-8,262 Reduced 53.21%
7,264 $333,000
Q3 2023

Oct 24, 2023

SELL
$15.81 - $27.8 $206,446 - $363,012
-13,058 Reduced 45.68%
15,526 $355,000
Q2 2023

Jul 18, 2023

SELL
$16.32 - $21.15 $416,160 - $539,325
-25,500 Reduced 47.15%
28,584 $471,000
Q1 2023

Apr 27, 2023

SELL
$16.88 - $34.24 $324,703 - $658,640
-19,236 Reduced 26.24%
54,084 $964,000
Q4 2022

Jan 19, 2023

BUY
$22.21 - $30.25 $770,798 - $1.05 Million
34,705 Added 89.87%
73,320 $0
Q3 2022

Oct 24, 2022

BUY
$4.3 - $30.85 $166,044 - $1.19 Million
38,615 New
38,615 $946,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.34B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Stratos Wealth Partners, Ltd. Portfolio

Follow Stratos Wealth Partners, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stratos Wealth Partners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Stratos Wealth Partners, Ltd. with notifications on news.